Alzheimer Disease: From Molecular Biology to Theraphy

ISBN-13: 9780817638795 / Angielski / Twarda / 1996 / 614 str.

Robert E. Becker; Ezio Giacobini

Opis

This volume reviews the new potential treatments and research in the area of Alzheimer's disease. Special attention is given to international developments in all fields relevant to new drug development. Topics discussed include: progress in the international harmonization of drug development guidelines for dementia drugs; bioethics and law; development of rating instruments; behavioural treatments; and the activities of the Reagan Foundation. The text integrates basic and clinical research findings, and provides evaluation of new approaches to therapy by world leaders in the field. The potential benefit for Alzheimer patients and families resulting from these research programmes, from molecular biology to clinical pharmacology, is reviewed and evaluated.

Spis treści

I. Pathological Basis of Therapy in Alzheimer’s Disease.- Criteria for the Diagnosis of Alzheimer’s Disease.- Criteria for the Clinical Diagnosis of Alzheimer’s Disease: Transcultural Aspects.- Clinical And Neuropathological Findings from Cerad.- Differentiating Alzheimer Disease and Vascular Dementia: Reframing the Question.- Neuropathology Of Alzheimer’s Disease.- Basis of Structural Alzheimer Disease and Some Pathogenic Concepts.- Regional Distribution of Neuropathological Changes in Alzheimer’s Disease.- Alzheimer Neurofibrillary Degeneration: A Feasible and Key Target for Therapeutics.- Diabetes and Dementia: A Retrospective Neuropathologic Study of Old Diabetics Compared to Non-Diabetic Controls.- Processing of Amyloid, Cytoskeletal Damage and Apolipoproteins.- Isoform-Specific Metabolism of Apolipoprotein E: Implications for Alzheimer’s Disease.- Apolipoprotein E4 and Cholinergic Activity in Alzheimer’s Disease.- A New Focus on Cytoskeletal Therapy in Alzheimer’s Disease.- Novel Cathepsin D Inhibitors Prevent the ?-Secretase-Derived Intracellular Formation of a 12 kDA Potentially Amyloidogenic Product in Human Cells.- Cellular and Test Tube Models of Amyloid-? Formation.- Effects of ?-Amyloid (1–40) Peptide Injection in the Nucleus Basalis.- ?Amyloid Precursor Protein — Role in Cognitive Brain Function?.- Peptides Inhibitor of Amyloidogenesis in Alzheimer’s Disease.- Cell Death: Excitotoxins, Apoptosis And Hypometabolism.- Apoptosis and Alzheimer’s Disease: A Self-Assembly and the Initiation of Apoptosis by Plasma Membrane Receptor Cross-Linking.- NMDA Receptor Dysfunction in Alzheimer’s Disease.- Role of Neuron-Glia Interactions in Brain Energy Metabolism: Implications for Neurodegenerative Disorders.- Neurotrophins, Growth Factors and Neuroprotectors.- Neurotrophins, Growth Factors and Mimetic Agents as Neuroprotectors in the Treatment of Alzheimer’s Disease.- Cortical Synaptogenesis and Behavioural Consequences in CNS Lesioned Animals Receiving Neurotrophic Factor Therapy.- Animal Models.- APP Knockout and APP Over-Expression in Transgenic Mice.- Alpha2c-Adrenoceptor Overexpressing Mice as a Model to Study Cognitive Functions of Alpha2-Adrenoceptors.- ?-APP-751 Transgenic Mice: Deficits In Learning And Memory.- II. The Cholinergic System in Brain.- Treatment of Alzheimer Disease.- Central and Peripheral Consequences of Cholinergic Imbalance in Alzheimer’s Disease.- The Anatomy of Monoaminergic-Cholinergic Interactions in the Primate Basal Forebrain.- Pharmacological Induction of Cholinergic Hypofunction as a Tool for Evaluating Cholinergic Therapies.- Rational Design of New Acetylcholinesterase Inhibitors.- Advances in Understanding Cholinergic Brain Neurons: Implications in the Use of Citicoline (CDP Choline) to Treat Stroke.- Cholinesterase Inhibitors in Alzheimer Disease Treatment.- Cholinesterase Inhibitors Do More than Inhibit Cholinesterase.- Long-Term Tacrine Treatment: Effect on Nursing Home Placement and Mortality.- Cholinesterase Inhibitors: An Overview of Their Mechanisms of Action.- Preclinical Pharmacology of Metrifonate: A Promise for Alzheimer Therapy.- Eptastigmine: A Cholinergic Approach to the Treatment of Alzheimer’s Disease.- Phenserine: A Selective, Long-Acting and Brain-Directed Acetylcholinesterase Inhibitor Affecting Cognition and ?-APP Processing.- An Overview of the Development of SDZ ENA 713: A Brain Selective Cholinesterase Inhibitor.- Preclinical and Clinical Progress with Huperzine A: A Novel Acetylcholinesterase Inhibitor.- P11467: An Orally-Active Acetylcholinesterase Inhibitor and ?2-Adrenoceptor Antagonist for Alzheimer’s Disease.- Cholinesterase Inhibitors as Therapy in Alzheimer’s Disease: Benefit to Risk Considerations in Clinical Application.- III. Nicotinic and Muscarinic Cholinergic Agonists.- Nicotinic Agonists.- Molecular Histochemistry of Nicotinic Receptors in Human Brain.- The Nicotinic Cholinergic System and ?-Amyloidosis.- RJR-2403: A CNS-Selective Nicotinic Agonist with Therapeutic Potential.- ABT-089: An Orally Effective Cholinergic Channel Modulator (ChCM) with Cognitive Enhancement and Neuroprotective Action.- Muscarinic Agonists and Antagonists.- Biochemistry, Pharmacodynamics and Pharmacokinetics of CI-1002: A Combined Anticholinesterase and Muscarinic Antagonist.- Muscarinic Partial Agonists in the Symptomatic Treatment of Alzheimer’s Disease.- Safety and Clinical Efficacy of S12024 in Patients with Mild to Moderate Alzheimer’s Disease.- Pharmacological Characterization of PD151832: An Ml Muscarinic Receptor Agonist.- The Potential of Antioxidant Therapy.- Novel Ml Agonists: From Symptomatic Treatment Towards Delaying the Progression of Alzheimer’s Disease.- Free Radical Scavengers Block the Actions of Amyloid on Neurons in Tissue Culture.- Therapeutic Strategies in Alzheimer’s Disease.- New Synthetic Bioantioxidants: Acetylcholinesterase (AChE).- Rationale to Treat Alzheimer’s Disease with Selegiline — Can We Prevent the Progression of the Disease?.- The Potential for Anti-Inflammatory Therapy.- Inflammatory Processes: Anti-Inflammatory Therapy.- Propentofylline: Preclinical Data.- Propentofylline (HWA 285): A Subgroup Analysis of Phase III Clinical Studies in Alzheimer’s Disease And Vascular Dementia.- Anapsos: New Therapeutic Strategies for Neurodegeneration and Brain Aging with Neuroimmunotrophic Factors.- IV. Development of New Therapies in Alzheimer Disease.- Design of Clinical Trials.- Clinical Trials to Prevent Alzheimer’s Disease in a Population At-Risk.- Effects on Decline or Deterioration.- The Bridging Study: Optimizing the Dose for PhaseII/III.- Assessment of Therapeutic Strategies for Slowing Progression of Alzheimer’s Disease.- Potential for Progress in the Therapeutics of Alzheimer’s Disease: Unanswered Questions.- Advances in Assessment.- The Alzheimer’s Disease Assessment Scale: Modifications That Can Enhance its Use in Future Clinical Trials.- An Item Pool to Assess Activities of Daily Living in Alzheimer’s Disease.- Severe Impairment Battery: A Potential Measure for Alzheimer’s Disease Clinical Trials.- Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression Of Change (ADCS-CGIC).- Advantages of the “Time-Index” Method for Measurement of Alzheimer Dementia: Assessment of Metrifonate Benefit.- SPECT and PET.- PET-Studies Using 11C-TZTP Derivatives for the Visualization of Muscarinic Receptors in the Human Brain.- PET Imaging of Nicotinic Receptors in Alzheimer’s Disease: Implication with Diagnosis and Drug Treatment.- Cerebral SPECT Imaging: Advances in Radio-Pharmaceuticals and Quantitative Analysis.- In Vivo Imaging of Anticholinesterase Drugs Used in Alzheimer’s Disease.- SPECT Scan And Efficacy of Therapy in Alzheimer’s Disease.- Potential Markers of Disease Progression and Drug Efficacy in Alzheimer’s Disease.- MRI and Cognitive Markers of Progression and Risk of Alzheimer Disease.- Brain Mapping and Transcranial Doppler Ultrasonography in Alzheimer Disease Drug Monitoring.- APOE Genotype and MRI Volumetry: Implication for Therapy.- Treatment of Behavioral and Psychosocial Disturbances.- Group Psychotherapy.- Non Cognitive Symptoms in Alzheimer’s Disease.- Depression And Alzheimer’s Disease.- Psychomotor Therapy and Alzheimer’s Disease.- Behavioral Techniques for Treatment of Patients with Alzheimer’s Disease.- Treatment of Psychosocial Disturbances.- Serotoninergic Symptomatology in Dementia.- V. Social Issue in Alzheimer Disease.- Legal and Ethical Issues.- Informed Consent and Alzheimer Disease Research: Institutional Review Board Policies And Practices.- Legal Issues in Alzheimer Disease Research in France.- Ethical Problems in Therapeutic Research in Alzheimer’s Disease Patients.- Making Consent Work in Alzheimer Disease Research.- Socio-Economic As pects of Alzheimer Disease Treatment.- Industry Perspectives on the Marketing of Anti-Alzheimer Disease Therapy.- CODEM: A Longitudinal Study on Alzheimer Disease Costs.- Health Economic Aspects of Alzheimer’s Disease and the Implications for Drug Development and Pricing.- International Harmonization of Drug Guidelines.- International Working Group for the Harmonization of Dementia Drug Guidelines: A Progress Report.- Developing Safe and Effective Antidementia Drugs.- A Japanese Perspective on the Work of the International Group on Harmonization of Drug Guidelines.- Research Priorities in Alzheimer Disease Treatment — An International Perspective.- The Ronald and Nancy Reagan Research Institute of The Alzheimer’s Association.- Author Index.

O autorze

Dr. Robert Becker ist Inhaber der Unternehmensberatung BBH-Marketing-Management in Bensheim, die sich darauf spezialisiert hat, Unternehmen bei der markt- und kundenorientierten Neuausrichtung zu begleiten. Sein Buch "Besser miteinander umgehen" ist 1994 erschienen.